Clinicians should be aware that it is possible to set SM goals regardless of the client's sex, age, or number of chronic conditions. Other possible influences on goal setting, such as severity of chronic conditions and challenges of the health care system, should be further investigated.

Corresponding author's email: toddcm@mcmaster.ca: Neutrophils contribute to the pathophysiology of asthma and their influx to the tissues may have implications on asthma Background symptoms and overall lung function. Migration of neutrophils occurs predominantly through activation of CXCR2 receptor by chemokines including IL-8 and GRO-alpha. A CXCR2 antagonist, SCH527123 has been developed to reduce the number of neutrophils migrating to the airways.This study investigated the effects of SCH527123 treatment on the level of neutrophils in bone marrow (BM), peripheral blood Objective: (PB) and induced sputum (IS) of mild asthmatic subjects.Thirteen mild atopic asthmatic subjects 18-65 years old completed a double-blind, placebo-controlled, multi-center crossover Methods: study. Subjects were required to have FEV >=70% of predicted, methacholine PC <=16 mg/ml, and PB neutrophil count >3000 L. PB 1 20 µ and IS were collected from all subjects before and after 8-10 days of treatment with 30 mg SCH527123 or placebo. BM was collected in a subset of 9 subjects at one investigational site. Differential counts and total cell counts were enumerated from all samples. PB was analyzed using ANOVA. Due to missing samples IS and BM results were analyzed using unpaired t-tests. There were no SAEs and the drug was well-tolerated. Means and SD are shown in Table 1. After SCH527123 treatment, the Results: number of PB neutrophils was reduced approximately 35% from baseline, compared to no change after placebo treatment (p= 0.04). The percent neutrophils decreased significantly in IS after active treatment but not after placebo treatment (p=0.